Schurch B, Reitz A, Tenti G
Neuro-Urology, Swiss Paraplegic Center, Balgrist University Hospital, Zurich, Switzerland.
Spinal Cord. 2004 Jun;42(6):338-41. doi: 10.1038/sj.sc.3101593.
Prospective, open label, cross-over-designed clinical study.
To evaluate the effectiveness of an instillation of lidocaine into the bladder with versus without electromotive drug administration (EMDA) to anesthetize the bladder before botulinum-A toxin injections.
Neurourology, Swiss Paraplegic Center, Balgrist University Hospital, Zurich, Switzerland.
In all, 28 patients with severe neurogenic detrusor overactivity but preserved bladder sensibility were treated with botulinum-A toxin injections into the detrusor muscle. A measure of 300 u of botulinum-A toxin (Botox) was injected at 30 sites sparing the trigone. Prior to the injection, the bladder was anesthesized with conventional lidocaine instillation in a group of 10 patients and with lidocaine instillation enhanced by EMDA in 28 patients. The patients scored the injection pain on a 10-point rating scale. Pain rating scores with versus without EMDA enhancement of the lidocaine instillation were analyzed and the costs of the EMDA procedure were compared to general/spinal anesthesia.
The mean pain score of the 10 patients who underwent the injections of Botox after conventional lidocaine instillation was 4.0 (SD 1.6). Following EMDA enhanced lidocaine instillation slight even or no pain occurred during the injections of Botox, and the mean pain score was 0.5 (SD 0.2). Compared to spinal or general anesthesia, the local anesthesia saved around 15% of the costs.
EMDA enhanced instillation of lidocaine enables a sufficient anesthesia of the bladder wall that ensures a painless application of the botulinum-A toxin injections into the detrusor muscle. This method may avoid general or spinal anesthesia in patients with preserved bladder sensibility. It ensures considerable cost reduction, avoids anesthesia-related risks and complications and enables the procedure on an outpatient basis.
前瞻性、开放标签、交叉设计的临床研究。
评估在注射肉毒杆菌A毒素前,膀胱灌注利多卡因联合与不联合电动药物导入(EMDA)对膀胱进行麻醉的效果。
瑞士苏黎世巴尔格里斯特大学医院瑞士截瘫中心神经泌尿学科室。
总共28例患有严重神经源性逼尿肌过度活动但膀胱感觉保留的患者接受了向逼尿肌注射肉毒杆菌A毒素的治疗。在避开三角区的30个部位注射了300单位的肉毒杆菌A毒素(保妥适)。注射前,10例患者采用传统利多卡因膀胱灌注麻醉,28例患者采用EMDA增强的利多卡因膀胱灌注麻醉。患者在10分制评分量表上对注射疼痛进行评分。分析利多卡因灌注联合与不联合EMDA增强时的疼痛评分,并将EMDA操作的成本与全身/脊髓麻醉的成本进行比较。
10例接受传统利多卡因灌注后注射保妥适的患者的平均疼痛评分为4.0(标准差1.6)。在EMDA增强利多卡因灌注后,注射保妥适期间甚至几乎没有疼痛发生,平均疼痛评分为0.5(标准差0.2)。与脊髓或全身麻醉相比,局部麻醉节省了约15%的成本。
EMDA增强的利多卡因灌注能够对膀胱壁进行充分麻醉,确保向逼尿肌注射肉毒杆菌A毒素时无痛。这种方法可以避免膀胱感觉保留患者的全身或脊髓麻醉。它确保了显著的成本降低,避免了与麻醉相关的风险和并发症,并使该操作可以在门诊进行。